Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.
Stephen D. Hall
Advertisement
Stephen D. Hall is senior research fellow, drug disposition, Eli Lilly and Co.
Articles by Stephen D. Hall
Advertisement
Latest Updated Articles
Enabling the Virtual Human Through Physiologically-based Pharmacokinetic ModelingPublished: March 16th 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
4
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
5
